For the quarter ending 2025-09-30, LYRA made $25K in revenue. -$5,984K in net income. Net profit margin of -23936.00%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 25 | 183 | 183 | 195 |
| Research and development | 4,047 | 5,110 | 4,876 | - |
| General and administrative | 2,236 | 3,501 | 3,263 | - |
| Impairment of property and equipment | 0 | 0 | - | - |
| Impairment of right-of-use assets | 0 | 0 | - | - |
| Restructuring and other related charges | -21 | 398 | 885 | - |
| Total operating expenses | 6,262 | 9,009 | 9,024 | 12,637 |
| Loss from operations | -6,237 | -8,826 | -8,841 | -12,442 |
| Interest income | 256 | 410 | 298 | 576 |
| Other income | 0 | 981 | - | - |
| Total other income | 256 | 1,391 | 298 | 576 |
| Loss before income tax expense | -5,981 | -7,435 | -8,543 | -11,866 |
| Income tax expense | 3 | 2 | 4 | 7 |
| Net loss | -5,984 | -7,437 | -8,547 | -11,873 |
| Unrealized holding income (loss) on short-term investments, net of tax | 0 | 0 | - | 24 |
| Comprehensive loss | -5,984 | -7,437 | -8,547 | -11,849 |
| Earnings per share, basic, total | -3.38 | -5.51 | -0.13 | -0.18 |
| Earnings per share, diluted, total | -3.38 | -5.51 | -0.13 | -0.18 |
| Weighted average number of shares outstanding, basic, total | 1,767,814 | 1,348,630 | 65,757,860 | 65,456,735 |
| Weighted average number of shares outstanding, diluted, total | 1,767,814 | 1,348,630 | 65,757,860 | 65,456,735 |
Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc. (LYRA)